Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale
Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophren...
Saved in:
Published in | Schizophrenia research Vol. 274; pp. 337 - 344 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.12.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia.
Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item–total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods.
Expert psychiatrists identified 11 relevant items, and patients rated 13 items as “very relevant” to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item–total correlations, 0.35–0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate.
A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals. |
---|---|
AbstractList | Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia.
Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods.
Expert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate.
A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals. Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia.BACKGROUNDImproved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia.Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods.METHODSThree approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods.Expert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate.RESULTSExpert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate.A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals.CONCLUSIONSA subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals. |
Author | Miguelez, Maia Meehan, Stine R. Farovik, Anja Milien, Mirline Kapadia, Shivani McIntyre, Roger S. Zhang, Zhen Brown, T. Michelle Ismail, Zahinoor Regnier, Stephane Alexandre |
Author_xml | – sequence: 1 givenname: Zahinoor surname: Ismail fullname: Ismail, Zahinoor email: ismailz@ucalgary.ca organization: Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada – sequence: 2 givenname: Stine R. surname: Meehan fullname: Meehan, Stine R. organization: Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark – sequence: 3 givenname: Anja surname: Farovik fullname: Farovik, Anja organization: Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark – sequence: 4 givenname: Maia surname: Miguelez fullname: Miguelez, Maia organization: Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA – sequence: 5 givenname: Shivani surname: Kapadia fullname: Kapadia, Shivani organization: Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA – sequence: 6 givenname: Stephane Alexandre surname: Regnier fullname: Regnier, Stephane Alexandre organization: Value Evidence Analytics and HEOR, H. Lundbeck A/S, Valby, Denmark – sequence: 7 givenname: Zhen surname: Zhang fullname: Zhang, Zhen organization: Medical and Real-World Data Analytics, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA – sequence: 8 givenname: T. Michelle surname: Brown fullname: Brown, T. Michelle organization: RTI Health Solutions, Research Triangle Park, NC, USA – sequence: 9 givenname: Mirline surname: Milien fullname: Milien, Mirline organization: RTI Health Solutions, Research Triangle Park, NC, USA – sequence: 10 givenname: Roger S. surname: McIntyre fullname: McIntyre, Roger S. organization: Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39461089$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1v1DAQhi1URLeFf4CQj1yy2I4T2xekqiq0UtUi0bvltSdbrxI7eLKVyq_H2y0cOc3XO_NqnjNyknICQj5ytuaM9192a_SPBXAtmJC1tWZMvyEr3qm2ER0zJ2TFjGCNMb08JWeIO8YY75h6R05bI3vOtFmR-QIRECdIC80Dnd0SD-kYB6CQtm4LL6OYaHWLv_NcLVN0dI8xbWlcYEI6lDzR5RHoj4xxiU9AXQr0Drbupfj5nEJV1MS7Ed6Tt4MbET68xnPy8O3q4fK6ub3_fnN5cdv4-o9uTLuRErTWIPuNaqUeVJDc644LP8jO9Ery4FSnXGA6COY6pRxwXQswWrfn5PPx7Fzyrz3gYqeIHsbRJch7tC0XXCglpKpSeZT6khELDHYucXLl2XJmD6jtzh5R2wPqQ7eirmufXh32mwnCv6W_bKvg61EA9c2nCKVeqXA9hFjALzbk-H-HPxxSk_g |
Cites_doi | 10.1186/s41687-022-00517-z 10.1097/00005053-200010000-00003 10.1177/07067437241233965 10.1016/j.jpsychires.2023.02.008 10.1186/s13075-015-0658-6 10.1186/s41687-021-00380-4 10.1016/j.jpsychires.2023.04.012 10.1017/neu.2020.8 10.1016/j.schres.2010.03.040 10.1001/jama.2015.15818 10.1093/schbul/13.2.261 10.1186/s41687-022-00468-5 10.1017/S0033291723002106 10.1007/s10865-005-9044-1 10.1007/s43441-019-00106-1 10.1186/s13195-018-0381-z 10.5116/ijme.4dfb.8dfd 10.1016/j.schres.2015.01.038 10.1037/a0033813 10.1176/appi.ajp.2015.14101275 10.1017/neu.2016.57 10.1111/j.1369-7625.2011.00704.x |
ContentType | Journal Article |
Copyright | 2024 The Authors Copyright © 2024. Published by Elsevier B.V. |
Copyright_xml | – notice: 2024 The Authors – notice: Copyright © 2024. Published by Elsevier B.V. |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.schres.2024.10.008 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1573-2509 |
EndPage | 344 |
ExternalDocumentID | 10_1016_j_schres_2024_10_008 39461089 S0920996424004456 |
Genre | Journal Article |
GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 6I. 7-5 71M 8P~ 9JM 9JO AABNK AACTN AADFP AAEDT AAEDW AAFTH AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXKI AAXLA AAXUO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABXDB ACDAQ ACGFS ACHQT ACIUM ACRLP ACXNI ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c2028-93b44e888e46b7348f7d41c8512cf4596741da757ad08d20a577ae1808de9883 |
IEDL.DBID | AIKHN |
ISSN | 0920-9964 1573-2509 |
IngestDate | Mon Oct 28 16:45:26 EDT 2024 Wed Nov 06 13:18:10 EST 2024 Sat Nov 02 12:31:40 EDT 2024 Sat Nov 09 15:59:26 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Schizophrenia Psychometrics Life engagement Patient interview Minimal clinically important difference |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2024. Published by Elsevier B.V. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2028-93b44e888e46b7348f7d41c8512cf4596741da757ad08d20a577ae1808de9883 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0920996424004456 |
PMID | 39461089 |
PQID | 3121277247 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_3121277247 crossref_primary_10_1016_j_schres_2024_10_008 pubmed_primary_39461089 elsevier_sciencedirect_doi_10_1016_j_schres_2024_10_008 |
PublicationCentury | 2000 |
PublicationDate | December 2024 |
PublicationDateYYYYMMDD | 2024-12-01 |
PublicationDate_xml | – month: 12 year: 2024 text: December 2024 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Schizophrenia research |
PublicationTitleAlternate | Schizophr Res |
PublicationYear | 2024 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | McIntyre, Ismail, Watling, Weiss, Meehan, Musingarimi, Thase (bb0095) 2022; 6 Adachi (bb0005) 2016 Correll, Ismail, McIntyre, Rafeyan, Thase (bb0040) 2022; 83 Weldring, Smith (bb0165) 2013; 6 Docherty, Baker, Eudicone, Mathew, Marcus, McQuade, Mankoski (bb0045) 2010; 120 Baran, Docherty (bb0015) 2008 European Medicines Agency (bb0050) 2020 Marder, Eriksson, Zhao, Hobart (bb0090) 2020; 32 Bartrés-Faz, Cattaneo, Solana, Tormos, Pascual-Leone (bb0020) 2018; 10 Therrien, Ward, Chokka, Habert, Ismail, McIntyre, MacKenzie (bb0145) 2024; 69 Scheier, Wrosch, Baum, Cohen, Martire, Matthews, Schulz, Zdaniuk (bb0125) 2006; 29 Vita, Barlati, Deste, Nibbio, Penn, Pinkham, McIntyre, Harvey (bb0155) 2023; 53 Guy (bb0055) 1976 R Core Team (bb0115) 2022 Kieffer, Miller, Chacko, Robertson (bb0080) 2020; 54 Therrien, Meehan, Weiss, Dine, Brown, MacKenzie (bb0140) 2022; 6 Thase, Ismail, Meehan, Weiss, Regnier, Larsen, McIntyre (bb0135) 2023; 161 Correll, Ismail, McIntyre, Rafeyan, Thase (bb0035) 2022; 83 Purnine, Carey, Maisto, Carey (bb0110) 2000; 188 Kane, Skuban, Ouyang, Hobart, Pfister, McQuade, Nyilas, Carson, Sanchez, Eriksson (bb0070) 2015; 164 Kay, Fiszbein, Opler (bb0075) 1987; 13 Tavakol, Dennick (bb0130) 2011; 2 Opler, Yavorsky, Daniel (bb0105) 2017; 14 Jolliffe (bb0065) 2002 Rai, Yazdany, Fortin, Aviña-Zubieta (bb0120) 2015; 17 Correll, Skuban, Ouyang, Hobart, Pfister, McQuade, Nyilas, Carson, Sanchez, Eriksson (bb0030) 2015; 172 Weiss, Meehan, Brown, Gupta, Mørup, Thase, McIntyre, Ismail (bb0160) 2021; 5 Hunter, O’Callaghan, Califf (bb0060) 2015; 314 Marder, Hakala, Josiassen, Zhang, Ouyang, Weiller, Weiss, Hobart (bb0085) 2017; 29 Bridges, Slawik, Schmeding, Reimer, Naber, Kuhnigk (bb0025) 2013; 16 McIntyre, Therrien, Ismail, Meehan, Miguelez, Larsen, Chen, MacKenzie, Thase (bb0100) 2023; 162 Trompetter, Ten Klooster, Schreurs, Fledderus, Westerhof, Bohlmeijer (bb0150) 2013; 25 American Psychiatric Association (bb0010) 2000 Tavakol (10.1016/j.schres.2024.10.008_bb0130) 2011; 2 Weldring (10.1016/j.schres.2024.10.008_bb0165) 2013; 6 European Medicines Agency (10.1016/j.schres.2024.10.008_bb0050) 2020 R Core Team (10.1016/j.schres.2024.10.008_bb0115) Kay (10.1016/j.schres.2024.10.008_bb0075) 1987; 13 Scheier (10.1016/j.schres.2024.10.008_bb0125) 2006; 29 Correll (10.1016/j.schres.2024.10.008_bb0030) 2015; 172 McIntyre (10.1016/j.schres.2024.10.008_bb0100) 2023; 162 Therrien (10.1016/j.schres.2024.10.008_bb0145) 2024; 69 Bartrés-Faz (10.1016/j.schres.2024.10.008_bb0020) 2018; 10 Correll (10.1016/j.schres.2024.10.008_bb0040) 2022; 83 Jolliffe (10.1016/j.schres.2024.10.008_bb0065) 2002 Vita (10.1016/j.schres.2024.10.008_bb0155) 2023; 53 Correll (10.1016/j.schres.2024.10.008_bb0035) 2022; 83 Marder (10.1016/j.schres.2024.10.008_bb0085) 2017; 29 Kane (10.1016/j.schres.2024.10.008_bb0070) 2015; 164 Rai (10.1016/j.schres.2024.10.008_bb0120) 2015; 17 American Psychiatric Association (10.1016/j.schres.2024.10.008_bb0010) 2000 Thase (10.1016/j.schres.2024.10.008_bb0135) 2023; 161 Docherty (10.1016/j.schres.2024.10.008_bb0045) 2010; 120 McIntyre (10.1016/j.schres.2024.10.008_bb0095) 2022; 6 Opler (10.1016/j.schres.2024.10.008_bb0105) 2017; 14 Baran (10.1016/j.schres.2024.10.008_bb0015) Bridges (10.1016/j.schres.2024.10.008_bb0025) 2013; 16 Kieffer (10.1016/j.schres.2024.10.008_bb0080) 2020; 54 Trompetter (10.1016/j.schres.2024.10.008_bb0150) 2013; 25 Purnine (10.1016/j.schres.2024.10.008_bb0110) 2000; 188 Adachi (10.1016/j.schres.2024.10.008_bb0005) 2016 Marder (10.1016/j.schres.2024.10.008_bb0090) 2020; 32 Hunter (10.1016/j.schres.2024.10.008_bb0060) 2015; 314 Guy (10.1016/j.schres.2024.10.008_bb0055) 1976 Therrien (10.1016/j.schres.2024.10.008_bb0140) 2022; 6 Weiss (10.1016/j.schres.2024.10.008_bb0160) 2021; 5 |
References_xml | – volume: 25 start-page: 1235 year: 2013 end-page: 1246 ident: bb0150 article-title: Measuring values and committed action with the Engaged Living Scale (ELS): psychometric evaluation in a nonclinical sample and a chronic pain sample publication-title: Psychol. Assess. contributor: fullname: Bohlmeijer – volume: 29 start-page: 278 year: 2017 end-page: 290 ident: bb0085 article-title: Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies publication-title: Acta Neuropsychiatr. contributor: fullname: Hobart – volume: 54 start-page: 709 year: 2020 end-page: 716 ident: bb0080 article-title: FDA reported use of patient experience data in 2018 drug approvals publication-title: Ther. Innov. Regul. Sci. contributor: fullname: Robertson – volume: 53 start-page: 7943 year: 2023 end-page: 7952 ident: bb0155 article-title: Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community publication-title: Psychol. Med. contributor: fullname: Harvey – volume: 188 start-page: 653 year: 2000 end-page: 661 ident: bb0110 article-title: Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders publication-title: J. Nerv. Ment. Dis. contributor: fullname: Carey – volume: 29 start-page: 291 year: 2006 end-page: 298 ident: bb0125 article-title: The Life Engagement Test: assessing purpose in life publication-title: J. Behav. Med. contributor: fullname: Zdaniuk – volume: 13 start-page: 261 year: 1987 end-page: 276 ident: bb0075 article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia publication-title: Schizophr. Bull. contributor: fullname: Opler – year: 2008 ident: bb0015 article-title: The “A” effect of aripiprazole. Presented at the American Psychiatric Association meeting. Washington, DC, May 3–8 2008 contributor: fullname: Docherty – volume: 10 start-page: 47 year: 2018 ident: bb0020 article-title: Meaning in life: resilience beyond reserve publication-title: Alzheimers Res. Ther. contributor: fullname: Pascual-Leone – volume: 2 start-page: 53 year: 2011 end-page: 55 ident: bb0130 article-title: Making sense of Cronbach’s alpha publication-title: Int. J. Med. Educ. contributor: fullname: Dennick – year: 1976 ident: bb0055 article-title: ECDEU Assessment Manual for Psychopharmacology, Revised contributor: fullname: Guy – volume: 6 start-page: 62 year: 2022 ident: bb0095 article-title: Patient-reported outcome measures for life engagement in mental health: a systematic review publication-title: J. Patient Rep. Outcomes contributor: fullname: Thase – volume: 164 start-page: 127 year: 2015 end-page: 135 ident: bb0070 article-title: A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia publication-title: Schizophr. Res. contributor: fullname: Eriksson – volume: 17 start-page: 143 year: 2015 ident: bb0120 article-title: Approaches for estimating minimal clinically important differences in systemic lupus erythematosus publication-title: Arthritis Res. Ther. contributor: fullname: Aviña-Zubieta – volume: 5 start-page: 128 year: 2021 ident: bb0160 article-title: Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: publication-title: J. Patient Rep. Outcomes contributor: fullname: Ismail – volume: 162 start-page: 71 year: 2023 end-page: 78 ident: bb0100 article-title: Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: publication-title: J. Psychiatr. Res. contributor: fullname: Thase – volume: 83 year: 2022 ident: bb0040 article-title: Patient functioning, life engagement, and treatment goals in schizophrenia publication-title: J. Clin. Psychiatry contributor: fullname: Thase – year: 2022 ident: bb0115 article-title: R: a language and environment for statistical computing contributor: fullname: R Core Team – volume: 161 start-page: 132 year: 2023 end-page: 139 ident: bb0135 article-title: Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR) publication-title: J. Psychiatr. Res. contributor: fullname: McIntyre – volume: 83 year: 2022 ident: bb0035 article-title: Patient functioning and life engagement: unmet needs in major depressive disorder and schizophrenia publication-title: J. Clin. Psychiatry contributor: fullname: Thase – start-page: 145 year: 2016 end-page: 160 ident: bb0005 article-title: Confirmatory factor analysis publication-title: Matrix-Based Introduction to Multivariate Data Analysis contributor: fullname: Adachi – year: 2002 ident: bb0065 article-title: Principal Component Analysis contributor: fullname: Jolliffe – volume: 6 start-page: 61 year: 2013 end-page: 68 ident: bb0165 article-title: Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) publication-title: Health. Serv. Insights contributor: fullname: Smith – volume: 14 start-page: 77 year: 2017 end-page: 81 ident: bb0105 article-title: Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions publication-title: Innov. Clin. Neurosci. contributor: fullname: Daniel – volume: 314 start-page: 2499 year: 2015 end-page: 2500 ident: bb0060 article-title: Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration publication-title: JAMA contributor: fullname: Califf – year: 2020 ident: bb0050 article-title: ICH Reflection Paper on Proposed ICH Guideline Work to Advance Patient Focused Drug Development contributor: fullname: European Medicines Agency – volume: 6 start-page: 111 year: 2022 ident: bb0140 article-title: Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews publication-title: J. Patient Rep. Outcomes contributor: fullname: MacKenzie – volume: 69 start-page: 513 year: 2024 end-page: 523 ident: bb0145 article-title: Adjunctive brexpiprazole for patient life engagement in major depressive disorder: a Canadian, phase 4, open-label, interventional study publication-title: Can. J. Psychiatry contributor: fullname: MacKenzie – volume: 16 start-page: 164 year: 2013 end-page: 176 ident: bb0025 article-title: A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia publication-title: Health Expect. contributor: fullname: Kuhnigk – volume: 172 start-page: 870 year: 2015 end-page: 880 ident: bb0030 article-title: Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial publication-title: Am. J. Psychiatry contributor: fullname: Eriksson – volume: 120 start-page: 199 year: 2010 end-page: 203 ident: bb0045 article-title: Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia publication-title: Schizophr. Res. contributor: fullname: Mankoski – volume: 32 start-page: 153 year: 2020 end-page: 158 ident: bb0090 article-title: analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia publication-title: Acta Neuropsychiatr. contributor: fullname: Hobart – year: 2000 ident: bb0010 article-title: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision contributor: fullname: American Psychiatric Association – volume: 6 start-page: 111 year: 2022 ident: 10.1016/j.schres.2024.10.008_bb0140 article-title: Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews publication-title: J. Patient Rep. Outcomes doi: 10.1186/s41687-022-00517-z contributor: fullname: Therrien – volume: 188 start-page: 653 year: 2000 ident: 10.1016/j.schres.2024.10.008_bb0110 article-title: Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders publication-title: J. Nerv. Ment. Dis. doi: 10.1097/00005053-200010000-00003 contributor: fullname: Purnine – volume: 69 start-page: 513 year: 2024 ident: 10.1016/j.schres.2024.10.008_bb0145 article-title: Adjunctive brexpiprazole for patient life engagement in major depressive disorder: a Canadian, phase 4, open-label, interventional study publication-title: Can. J. Psychiatry doi: 10.1177/07067437241233965 contributor: fullname: Therrien – volume: 161 start-page: 132 year: 2023 ident: 10.1016/j.schres.2024.10.008_bb0135 article-title: Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR) publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2023.02.008 contributor: fullname: Thase – volume: 17 start-page: 143 year: 2015 ident: 10.1016/j.schres.2024.10.008_bb0120 article-title: Approaches for estimating minimal clinically important differences in systemic lupus erythematosus publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-015-0658-6 contributor: fullname: Rai – volume: 5 start-page: 128 year: 2021 ident: 10.1016/j.schres.2024.10.008_bb0160 article-title: Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews publication-title: J. Patient Rep. Outcomes doi: 10.1186/s41687-021-00380-4 contributor: fullname: Weiss – volume: 162 start-page: 71 year: 2023 ident: 10.1016/j.schres.2024.10.008_bb0100 article-title: Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: post hoc analysis of Inventory of Depressive Symptomatology Self-Report data publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2023.04.012 contributor: fullname: McIntyre – volume: 83 year: 2022 ident: 10.1016/j.schres.2024.10.008_bb0035 article-title: Patient functioning and life engagement: unmet needs in major depressive disorder and schizophrenia publication-title: J. Clin. Psychiatry contributor: fullname: Correll – volume: 32 start-page: 153 year: 2020 ident: 10.1016/j.schres.2024.10.008_bb0090 article-title: Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia publication-title: Acta Neuropsychiatr. doi: 10.1017/neu.2020.8 contributor: fullname: Marder – year: 2002 ident: 10.1016/j.schres.2024.10.008_bb0065 contributor: fullname: Jolliffe – volume: 120 start-page: 199 year: 2010 ident: 10.1016/j.schres.2024.10.008_bb0045 article-title: Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2010.03.040 contributor: fullname: Docherty – volume: 314 start-page: 2499 year: 2015 ident: 10.1016/j.schres.2024.10.008_bb0060 article-title: Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration publication-title: JAMA doi: 10.1001/jama.2015.15818 contributor: fullname: Hunter – start-page: 145 year: 2016 ident: 10.1016/j.schres.2024.10.008_bb0005 article-title: Confirmatory factor analysis contributor: fullname: Adachi – volume: 13 start-page: 261 year: 1987 ident: 10.1016/j.schres.2024.10.008_bb0075 article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia publication-title: Schizophr. Bull. doi: 10.1093/schbul/13.2.261 contributor: fullname: Kay – ident: 10.1016/j.schres.2024.10.008_bb0015 contributor: fullname: Baran – volume: 6 start-page: 62 year: 2022 ident: 10.1016/j.schres.2024.10.008_bb0095 article-title: Patient-reported outcome measures for life engagement in mental health: a systematic review publication-title: J. Patient Rep. Outcomes doi: 10.1186/s41687-022-00468-5 contributor: fullname: McIntyre – volume: 53 start-page: 7943 year: 2023 ident: 10.1016/j.schres.2024.10.008_bb0155 article-title: Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community publication-title: Psychol. Med. doi: 10.1017/S0033291723002106 contributor: fullname: Vita – volume: 83 year: 2022 ident: 10.1016/j.schres.2024.10.008_bb0040 article-title: Patient functioning, life engagement, and treatment goals in schizophrenia publication-title: J. Clin. Psychiatry contributor: fullname: Correll – volume: 6 start-page: 61 year: 2013 ident: 10.1016/j.schres.2024.10.008_bb0165 article-title: Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) publication-title: Health. Serv. Insights contributor: fullname: Weldring – volume: 14 start-page: 77 year: 2017 ident: 10.1016/j.schres.2024.10.008_bb0105 article-title: Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions publication-title: Innov. Clin. Neurosci. contributor: fullname: Opler – volume: 29 start-page: 291 year: 2006 ident: 10.1016/j.schres.2024.10.008_bb0125 article-title: The Life Engagement Test: assessing purpose in life publication-title: J. Behav. Med. doi: 10.1007/s10865-005-9044-1 contributor: fullname: Scheier – volume: 54 start-page: 709 year: 2020 ident: 10.1016/j.schres.2024.10.008_bb0080 article-title: FDA reported use of patient experience data in 2018 drug approvals publication-title: Ther. Innov. Regul. Sci. doi: 10.1007/s43441-019-00106-1 contributor: fullname: Kieffer – year: 2000 ident: 10.1016/j.schres.2024.10.008_bb0010 contributor: fullname: American Psychiatric Association – volume: 10 start-page: 47 year: 2018 ident: 10.1016/j.schres.2024.10.008_bb0020 article-title: Meaning in life: resilience beyond reserve publication-title: Alzheimers Res. Ther. doi: 10.1186/s13195-018-0381-z contributor: fullname: Bartrés-Faz – volume: 2 start-page: 53 year: 2011 ident: 10.1016/j.schres.2024.10.008_bb0130 article-title: Making sense of Cronbach’s alpha publication-title: Int. J. Med. Educ. doi: 10.5116/ijme.4dfb.8dfd contributor: fullname: Tavakol – year: 2020 ident: 10.1016/j.schres.2024.10.008_bb0050 contributor: fullname: European Medicines Agency – ident: 10.1016/j.schres.2024.10.008_bb0115 contributor: fullname: R Core Team – volume: 164 start-page: 127 year: 2015 ident: 10.1016/j.schres.2024.10.008_bb0070 article-title: A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2015.01.038 contributor: fullname: Kane – volume: 25 start-page: 1235 year: 2013 ident: 10.1016/j.schres.2024.10.008_bb0150 article-title: Measuring values and committed action with the Engaged Living Scale (ELS): psychometric evaluation in a nonclinical sample and a chronic pain sample publication-title: Psychol. Assess. doi: 10.1037/a0033813 contributor: fullname: Trompetter – volume: 172 start-page: 870 year: 2015 ident: 10.1016/j.schres.2024.10.008_bb0030 article-title: Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2015.14101275 contributor: fullname: Correll – year: 1976 ident: 10.1016/j.schres.2024.10.008_bb0055 contributor: fullname: Guy – volume: 29 start-page: 278 year: 2017 ident: 10.1016/j.schres.2024.10.008_bb0085 article-title: Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies publication-title: Acta Neuropsychiatr. doi: 10.1017/neu.2016.57 contributor: fullname: Marder – volume: 16 start-page: 164 year: 2013 ident: 10.1016/j.schres.2024.10.008_bb0025 article-title: A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia publication-title: Health Expect. doi: 10.1111/j.1369-7625.2011.00704.x contributor: fullname: Bridges |
SSID | ssj0001507 |
Score | 2.4965265 |
Snippet | Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 337 |
SubjectTerms | Life engagement Minimal clinically important difference Patient interview Psychometrics Schizophrenia |
Title | Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale |
URI | https://dx.doi.org/10.1016/j.schres.2024.10.008 https://www.ncbi.nlm.nih.gov/pubmed/39461089 https://www.proquest.com/docview/3121277247 |
Volume | 274 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na-MwEB2a9LKXpWW7u9l-MAu9prFl2ZKPoTSkWxoW0kJuRrbkkGVxwvbj2N_eGVkO7SEU9miBsJiRZ97Ib54AzqneUhXlEYp-ouajGzXMLXdymcgIEddW-1tLbmfZ9F7-WqSLPbjsemGYVhlifxvTfbQOI6NgzdFmtRrNo5zbPgk_8zYkHNCDfUpHQvdhf3x9M51tAzJjHi-5R5UST-g66DzNi2pIqmupUBTywtO89K4MtQuB-kw0OYDPAULiuF3lIey55gtsxluJTVzXGORS8e-qduiaZaC44KrBh7c0O2Te-xL9fWzIrSZIgBB_eybXs0PTWJy5pRcHx3kQN8A5-dUdwd3k6u5yOgy3KQwrwUdoeVJK6ajgdTIrWdOmVlbGFSEuUdUyzTPCFtaoVBkbaSsikyplXKzpweVaJ1-h36wb9x3QCqXKpEpdlGhpE1kqnZbSVCorqd7K5ACGnQGLTauZUXRksj9Fa_CCDc6jZPABqM7KxTvfFxTWP5j5s3NKQZ8F_-swjVs_PRRJzNL1Skg1gG-tt7ZrSXIWmdf5j_9-7zF84qeW1nIC_cd_T-6UwMljeQa9i5f4LGzBV53g4q8 |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA4-DnoRxdf6HMHrut00bdLjIsr6WoRdwVtIm3RZke7iqr_fmTRd9CCCl0JTQstMMvkm_eYLY-eYb8kC1xGMfrykrRvZzixVcpnIcN4trfKnljwM0v6TuH1OnpfYZVMLQ7TKEPvrmO6jdWjpBGt2ZpNJZxhlVPaJ-JmGIeKAZbaK1wxn52rv5q4_WARkwjxecg8zJerQVNB5mhfmkJjXYqLIxYWneanfVqjfEKhfia432UaAkNCrv3KLLblqm816C4lNmJYQ5FLhdVI6cNU4UFxgUsH8O80OiPc-Bn8eG1CpCSAghEfP5Pp0YCoLAzf24uAwDOIGMES_uh02ur4aXfbb4TSFdsFpCy2LcyEcJrxOpDlp2pTSim6BiIsXpUiyFLGFNTKRxkbK8sgkUhrXVXjjMqXiXbZSTSu3z8ByKfO4SFwUK2FjkUuV5MIUMs0x30pFi7UbA-pZrZmhGzLZi64Nrsng1IoGbzHZWFn_8L3GsP5Hz7PGKRqnBf3rMJWbfsx13CXpesmFbLG92luLb4kzEplX2cG_33vK1vqjh3t9fzO4O2Tr9KSmuByxlfe3D3eMQOU9PwkD8QscA-Sj |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+patient+life+engagement+in+schizophrenia+using+items+from+the+Positive+and+Negative+Syndrome+Scale&rft.jtitle=Schizophrenia+research&rft.au=Ismail%2C+Zahinoor&rft.au=Meehan%2C+Stine+R&rft.au=Farovik%2C+Anja&rft.au=Miguelez%2C+Maia&rft.date=2024-12-01&rft.eissn=1573-2509&rft.volume=274&rft.spage=337&rft_id=info:doi/10.1016%2Fj.schres.2024.10.008&rft_id=info%3Apmid%2F39461089&rft.externalDocID=39461089 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-9964&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-9964&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-9964&client=summon |